Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12555905 | 0.87 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL16248899 | 0.87 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL13805619 | 0.85 | MAPK1 (0.44) | MAPK1 | |
| SCHEMBL13034048 | 0.82 | MAPK1 (0.55) | MAPK1 | |
| SCHEMBL24910631 | 0.80 | MAPK1 (0.40) | MAPK1 | |
| SCHEMBL22995685 | 0.77 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL116799 | 0.76 | MAPK1 (0.56) | MAPK1 | |
| SCHEMBL8083397 | 0.76 | MAPK1 (0.56) | MAPK1 | |
| SCHEMBL4189322 | 0.76 | MAPK1 (0.56) | MAPK1 | |
| SCHEMBL4181754 | 0.76 | MAPK1 (0.56) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | MAPK1 237/4885PRKCA 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.